Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tencent Music Entertainment Group operates online music entertainment platforms to provide music streaming, online karaoke, and live streaming services in the People's Republic of China. It offers QQ Music, Kugou Music, and Kuwo Music that enable users to discover and listen to music in personalized ways; and WeSing, which enables users to have fun by singing and interacting with friends, sharing their singing performances with friends, and discovering songs that others have sung. The company also operates Kugou Music, Kuwo Music, WeSing, QQ Music, Kugou Live, and Kuwo Live that provides an interactive online stage for performers and users to showcase their talent and engage with those interested in their performance; and Kuwo Changting, an audio platform that offers users various audio content, including audio books, cross-talks, radio dramas, and other entertainment. In addition, it sells music-related merchandise, including Kugou headsets, smart speakers, WeSing karaoke microphones, and Hi-Fi systems; and offers online music event ticketing services, as well as services to smart device and automobile makers to build and operate music services on devices and vehicles. Tencent Music Entertainment Group has a strategic partnership with China Literature. The company is headquartered in Shenzhen, China. Tencent Music Entertainment Group is a subsidiary of Tencent Holdings Limited.

Tencent Music Entertainment Group

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

/PRNEWSWIRE/ -- TENCENT MUSIC ENTERTAINMENT GROUP ("TME," OR THE "COMPANY") (NYSE: TME AND HKEX: 1698), THE LEADING ONLINE MUSIC AND AUDIO ENTERTAINMENT

TENCENT MUSIC ENTERTAINMENT GROUP ANNOUNCES THIRD QUARTER 2025 UNAUDITED FINANCIAL RESULTS

FDA'S MARKETING AUTHORIZATION FOR PROSENSEFOR LOW-RISK BREAST CANCER RECEIVED FOLLOWING THE TME FALL SUMMITMARKETING AUTHORIZATION EXPECTED TO FURTHER DRIVE COMMERCIAL TRACTION BASED ON THE HIGH LEVEL OF INTEREST RECEIVED AT THE ROUNDTABLE EVENT CAESAREA, ISRAEL , OCT. 13, 2025 /PRNEWSWIRE/ --ICECURE MEDICAL LTD. (NASDAQ: ICCM) ("ICECURE", "ICECURE MEDICAL" OR THE "COMPANY"), DEVELOPER OF MINIMALLY-INVASIVE CRYOABLATION TECHNOLOGY THAT DESTROYS TUMORS BY FREEZING AS AN OPTION TO SURGICAL TUMOR REMOVAL, TODAY ANNOUNCED ITS PARTICIPATION AT APTITUDE HEALTH'S TME TAKE THE LEAD IN BREAST CANCER CARE FALL SUMMIT 2025, WHICH TOOK PLACE ON SEPTEMBER 2627, 2025, IN NEW ORLEANS, LOUISIANA.

ICECURE'S PROSENSE SHOWCASED AT TME FALL SUMMIT: "TAKE THE LEAD IN BREAST CANCER CARE" ROUNDTABLE HIGHLIGHTING CRYOABLATION ADVANCES

INDUSTRY-LEADING EVENT GATHERS INFLUENTIAL BREAST CARE PHYSICIANS TO EXPLORE BEST PRACTICES AND THE FUTURE OF PATIENT CARE TORONTO AND DALLAS , SEPT. 26, 2025 /PRNEWSWIRE/ - PERIMETER MEDICAL IMAGING AI , INC. (TSXV: PINK) (OTCQX: PYNKF) ("PERIMETER" OR THE "COMPANY"), A COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, ANNOUNCED TODAY THAT IT WILL BE EXHIBITING AT APTITUDE HEALTH/TME'S FALL SUMMIT, "TAKE THE LEAD IN BREAST CANCER CARE," IN NEW ORLEANS, SEPT.

PERIMETER SHOWCASES INNOVATIVE IMAGING TECHNOLOGY AT APTITUDE HEALTH/TME'S FALL SUMMIT ON BREAST CANCER CARE

SHENZHEN, CHINA , SEPT. 23, 2025 /PRNEWSWIRE/ -- TENCENT MUSIC ENTERTAINMENT GROUP ("TME", OR THE "COMPANY") (NYSE: TME AND HKEX: 1698), THE LEADING ONLINE MUSIC AND AUDIO ENTERTAINMENT PLATFORM IN CHINA, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE "BOARD") APPROVED THE APPOINTMENT OF MS.

TENCENT MUSIC ENTERTAINMENT GROUP ANNOUNCES NEW AUDIT COMMITTEE MEMBER

BOSTON--(BUSINESS WIRE)--CANCER GRAND CHALLENGES ANNOUNCES SEVEN NEW CHALLENGES REPRESENTING SOME OF THE TOUGHEST QUESTIONS FACING CANCER RESEARCH TODAY.

CANCER GRAND CHALLENGES ANNOUNCES SEVEN NEW CHALLENGES REPRESENTING SOME OF THE TOUGHEST QUESTIONS FACING CANCER RESEARCH TODAY

EXPANDING TME'S GLOBAL FOOTPRINT TO ELEVATE INTERNATIONAL MUSIC EXPERIENCES SHENZHEN, CHINA , OCT. 17, 2024 /PRNEWSWIRE/ -- TENCENT MUSIC ENTERTAINMENT GROUP (TME) TODAY ANNOUNCED A STRATEGIC PARTNERSHIP WITH GALAXY CORPORATION, THE AGENCY REPRESENTING THE INFLUENTIAL GLOBAL MUSICIAN G-DRAGON, FOR HIS UPCOMING REGIONAL TOUR. THE COLLABORATION MARKS A SIGNIFICANT STEP FORWARD IN TME'S AMBITIONS TO EXPAND ITS GLOBAL PRESENCE AND FURTHER SOLIDIFY ITS POSITION IN THE INTERNATIONAL MUSIC SCENE.

TENCENT MUSIC ENTERTAINMENT GROUP INKS STRATEGIC PARTNERSHIP WITH GALAXY CORPORATION

SINGAPORE KICKS OFF THE FIRST STOP OF TME'S MUSIC JOURNEY TO THE WORLD SHENZHEN, CHINA , SEPT. 12, 2024 /PRNEWSWIRE/ -- ON SEPTEMBER 11, 2024 , TENCENT MUSIC ENTERTAINMENT GROUP (TME) ANNOUNCED THE LAUNCH OF ITS GLOBAL MUSIC OUTREACH INITIATIVE, WHICH WILL BRING TOGETHER TALENTED CHINESE MUSIC ARTISTS AND THEIR WORKS TO BE SHOWCASED ON PROMINENT STAGES WORLDWIDE.

TENCENT MUSIC ENTERTAINMENT GROUP LAUNCHES GLOBAL MUSIC OUTREACH INITIATIVE

THE SON-1010 STUDIES HAVE TOGETHER ENROLLED 61 SUBJECTS, TO DATE, AS DOSE ESCALATION CONTINUES IN SB101 AND SB221 AT HIGHER LEVELSPATIENTS HAVE RECEIVED UP TO 25 CYCLES OF SON-1010 AS MONOTHERAPY AND 10 CYCLES OF SON-1010 WITH ATEZOLIZUMAB (TECENTRIQ) WITHOUT DOSE-LIMITING TOXICITY AT ANY DOSE LEVELCYTOKINE DATA REVEALS ABOUT 10-FOLD EXTENDED HALF-LIFE FOR SON-1010 COMPARED WITH RHIL-12 THAT INDUCES PROLONGED AND CONTROLLED IFN RESPONSES, WITH NO EVIDENCE OF CYTOKINE RELEASE SYNDROME AT ANY DOSECLINICAL BENEFIT WAS SEEN AT FOUR MONTHS POST-INITIATION OF DOSING IN 35% OF EVALUABLE PATIENTS (8/23) WITH ADVANCED SOLID TUMORS PRINCETON, NJ / ACCESSWIRE / MAY 20, 2024 / SONNET BIOTHERAPEUTICS HOLDINGS, INC. (NASDAQ:SONN) (THE "COMPANY" OR "SONNET"), A CLINICAL-STAGE COMPANY DEVELOPING TARGETED IMMUNOTHERAPEUTIC DRUGS, ANNOUNCED TODAY THAT THE SAFETY OF SON-1010 DOSING HAS BEEN FORMALLY REVIEWED IN BOTH OF THE CURRENT PHASE 1 CLINICAL TRIALS AND THE COMPANY IS NOW INCREASING THE TARGET DOSE OF SON-1010 DURING DOSE ESCALATION. SON-1010 IS A PROPRIETARY VERSION OF RECOMBINANT HUMAN INTERLEUKIN-12 (RHIL-12), CONFIGURED USING SONNET'S FULLY HUMAN ALBUMIN BINDING (FHAB) PLATFORM, WHICH EXTENDS THE HALF-LIFE AND ACTIVITY OF THE IL-12 COMPONENT DUE TO BINDING NATIVE ALBUMIN IN THE SERUM AND TARGETS THE TUMOR MICROENVIRONMENT (TME) BY STRONGLY BINDING GP60 AND SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE (SPARC). SB101 IS A PHASE 1 MULTIPLE-ASCENDING DOSE (MAD) TRIAL IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS (NCT05352750) THAT COMMENCED IN Q2 2022 AND IS CURRENTLY ENROLLING THE SIXTH DOSE COHORT. SB221 IS A PHASE 1B/2A DOSE-ESCALATION AND PROOF-OF-CONCEPT STUDY OF THE COMBINATION OF SON-1010 WITH ATEZOLIZUMAB (IN COLLABORATION WITH GENENTECH, A MEMBER OF THE ROCHE GROUP), IN A STUDY FOCUSED ON PLATINUM-RESISTANT OVARIAN CANCER (PROC) (NCT05756907) THAT STARTED IN Q4 2023, NOW ENROLLING THE FOURTH DOSE COHORT. IN ADDITION, SON-1010 WAS STUDIED IN SB102, WHICH WAS A PHASE 1 SING

SONNET BIOTHERAPEUTICS ANNOUNCES UPDATED CLINICAL DATA FOR SON-1010 AS MONOTHERAPY OR COMBINED WITH AN ANTI-PD-L1, ALONG WITH AN INCREASE IN THE DOSE-ESCALATION TARGET

SHENZHEN, CHINA , APRIL 18, 2024 /PRNEWSWIRE/ -- TENCENTMUSIC ENTERTAINMENT GROUP ("TME", OR THE "COMPANY") (NYSE: TME AND HKEX: 1698), THE LEADING ONLINE MUSIC AND AUDIO ENTERTAINMENT PLATFORM INCHINA, TODAY ANNOUNCED THAT IT HAS FILED ITS ANNUAL REPORT ON FORM 20-F THAT INCLUDES ITS AUDITED FINANCIAL STATEMENTS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 WITH THE SECURITIES AND EXCHANGE COMMISSION (THE "SEC") ON APRIL 18, 2024, U. S. EASTERN TIME.

TENCENT MUSIC ENTERTAINMENT GROUP FILED 2023 ANNUAL REPORT ON FORM 20-F

SHENZHEN, CHINA , FEB. 20, 2024 /PRNEWSWIRE/ -- TENCENTMUSIC ENTERTAINMENT GROUP ("TME", OR THE "COMPANY") (NYSE: TME AND HKEX: 1698), THE LEADING ONLINE MUSIC AND AUDIO ENTERTAINMENT PLATFORM INCHINA, TODAY ANNOUNCED THAT IT WILL REPORT ITS UNAUDITED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR OF 2023 BEFORE THE U.S. MARKET OPENS ONTUESDAY, MARCH 19, 2024. TME'S MANAGEMENT WILL HOST A TENCENT MEETING WEBINAR ONTUESDAY, MARCH 19, 2024, AT7:00 A.M.

Tencent Music Entertainment Group

TME

Price

Financial Reports

No items found.

Press Releases

Tencent Music Entertainment Group

TME.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TME